We are live on ! Find out more
AUTL

Autolus Therapeutics
AUTL

65 hedge funds and large institutions have $195M invested in Autolus Therapeutics in 2023 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 20 increasing their positions, 11 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

454% more call options, than puts

Call options by funds: $72K | Put options by funds: $13K

82% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 11

4% less capital invested

Capital invested by funds: $204M → $195M (-$9.03M)

3.41% less ownership

Funds ownership: 64.69% → 61.28% (-3.4%)

8% less funds holding

Funds holding: 71 → 65 (-6)

36% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 14

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
65
Holders Change
-6
Holders Change %
-8.45%
% of All Funds
1.04%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
9
Increased
20
Reduced
11
Closed
14
Calls
$72K
Puts
$13K
Net Calls
+$59K
Net Calls Change
-$272K

Top Buyers

Rank Fund Capital Flow
1
TAM
TFG Asset Management
Cayman Islands
+$3.32M
2
UOC
UBS O'Connor
Illinois
+$1.48M
3
BlackRock
BlackRock
New York
+$925K
4
Millennium Management
Millennium Management
New York
+$458K
5
IAM
Innovis Asset Management
Illinois
+$247K

Top Sellers

Rank Fund Capital Flow
1
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$2.44M
2
CH
CVI Holdings
Delaware
-$2.35M
3
Capital World Investors
Capital World Investors
California
-$1.19M
4
AC
Armistice Capital
New York
-$1.08M
5
SFM
Sphera Funds Management
Israel
-$950K
Name Holding Trade Value Shares
Change 		Change in
Stake
SP
1
Syncona Portfolio
Guernsey
$39.3M – – –
Blackstone Inc
2
Blackstone Inc
New York
$37.7M – – –
DTC
3
Deep Track Capital
Connecticut
$27.6M – – –
TAM
4
TFG Asset Management
Cayman Islands
$18.4M +$3.32M +1,700,000 +20%
AC
5
Armistice Capital
New York
$17.8M -$1.08M -552,000 -5%
NCM
6
Nantahala Capital Management
Connecticut
$14.2M -$176K -90,205 -1%
FLSM
7
Frazier Life Sciences Management
California
$6.89M – – –
OAMG
8
Odey Asset Management Group
United Kingdom
$4.6M – – –
PL
9
Perpetual Ltd
Australia
$3.42M +$3.63M +1,858,091 New
Schroder Investment Management Group
10
Schroder Investment Management Group
United Kingdom
$3.08M – – –
Citadel Advisors
11
Citadel Advisors
Florida
$2.88M -$414K -211,753 -12%
LCM
12
Laurion Capital Management
New York
$2.76M – – –
DCM
13
DAFNA Capital Management
California
$2.16M – – –
BlackRock
14
BlackRock
New York
$1.63M +$925K +473,247 +115%
UOC
15
UBS O'Connor
Illinois
$1.39M +$1.48M +757,008 New
AI
16
Alphabet Inc
California
$1.28M – – –
LCP
17
LGT Capital Partners
Switzerland
$1.01M – – –
Wells Fargo
18
Wells Fargo
California
$897K +$218K +111,708 +30%
JP Morgan Chase
19
JP Morgan Chase
New York
$811K -$103K -52,484 -11%
MCM
20
MAI Capital Management
Ohio
$798K -$95.8K -48,987 -10%
ECM
21
ExodusPoint Capital Management
New York
$761K +$141K +72,044 +21%
CAM
22
Cormorant Asset Management
Massachusetts
$722K – – –
Millennium Management
23
Millennium Management
New York
$663K +$458K +234,495 +187%
IC
24
Ikarian Capital
Texas
$479K – – –
HCA
25
Harbor Capital Advisors
Illinois
$409K +$150K +76,834 +53%
1
2 3 4

AUTL Hedge Fund Activity: Q1 2023 in Review

65 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Autolus Therapeutics (AUTL) for Q1 2023, worth a combined $195M — down 4.4% from $204M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of AUTL and 9 opened new positions — a net loss of 5 holders — while 11 trimmed existing stakes and 20 added.

The largest buyer was TFG Asset Management, adding an estimated $3.32M. The largest seller was Alyeska Investment Group, cutting an estimated $2.44M.

  • 65 institutional investors held Autolus Therapeutics (AUTL) as of Q1 2023, down from 71 in Q4 2022.
  • Funds reported $195M of Autolus Therapeutics stock for Q1 2023, down 4.4% quarter-over-quarter.
  • 9 funds opened new Autolus Therapeutics positions in Q1 2023 and 14 closed out, a net change of -5 holders.
  • The largest Autolus Therapeutics buyer in Q1 2023 was TFG Asset Management, an estimated $3.32M added.
  • The largest Autolus Therapeutics seller in Q1 2023 was Alyeska Investment Group, an estimated $2.44M sold.

Based on aggregated 13F filings for Q1 2023.